Funding
Outside funding helps Dr. Abdel advance his research. Dr. Abdel currently receives funding from the National Institutes of Health and Regenerative Medicine Minnesota, allowing the Orthopedic Genetic Host Variation Lab to study the pathogenesis of arthrofibrosis and new treatment options.
| Investigator & Role |
Grant Title |
Funding Source |
Duration |
| Matthew P. Abdel, M.D. |
Pathologic Role of Inflammation and Mechanistic Analysis of Myofibroblastogenesis in Arthrofibrosis (R01 AR072597) |
National Institutes of Health |
04/01/2018 - 03/31/2023 |
| Matthew P. Abdel, M.D. |
First-in-Class Pharmacotherapies for Arthrofibrosis (RMM 091620 TR 010) |
Regenerative Medicine Minnesota |
03/01/2021 - 02/28/2023 |